VAXIMM is primarily focused on developing active immunotherapies for patients suffering from cancer. The company’s initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA, Darmstadt, Germany.

Team Members
more about
Jasper Bos
more about
Bram Vanparys
Latest News Entry
VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting

Results include one objective response, three patients with stable disease

all portfolio news